Skip to main content

Poteligeo Disease Interactions

There is 1 disease interaction with Poteligeo (mogamulizumab).

Moderate

Mogamulizumab (applies to Poteligeo) autoimmune disease

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Autoimmune Disorder

Fatal and life-threatening immune-mediated complications have been reported in recipients of mogamulizumab. Grade 3 or higher immune-mediated or possibly immune-mediated reactions have included myositis, myocarditis, polymyositis, hepatitis, pneumonitis, and a variant of Guillain- Barré syndrome. Interrupt or permanently discontinue therapy as appropriate for suspected immune-mediated adverse reactions. Consider the benefit/risk of using mogamulizumab in patients with a history of autoimmune disease.

Switch to professional interaction data

Poteligeo drug interactions

There are 171 drug interactions with Poteligeo (mogamulizumab).


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

See also:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.